Makale detayı · 2015
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS
Dergi
PLoS ONE- Yıl
- 2015
- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS dergi adı PLoS ONE
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
OpenAlex · İngilizce
BACKGROUND: Multiple Sclerosis is more common in women than men and females have more relapses than men. In a large international cohort we have evaluated the effect of gender on disability accumulation and disease progression to determine if male MS patients have a worse clinical outcome than females. METHODS: Using the MSBase Registry, data from 15,826 MS patients from 25 countries was analysed. Changes in the severity of MS (EDSS) were compared between sexes using a repeated measures analysis in generalised linear mixed models. Kaplan-Meier analysis was used to test for sex difference in the time to reach EDSS milestones 3 and 6 and the secondary progressive MS. RESULTS: In relapse onset MS patients (n = 14,453), males progressed significantly faster in their EDSS than females (0.133 vs 0.112 per year, P<0.001,). Females had a reduced risk of secondary progressive MS (HR (95% CI) = 0.77 (0.67 to 0.90) P = 0.001). In primary progressive MS (n = 1,373), there was a significant increase in EDSS over time in males and females (P<0.001) but there was no significant sex effect on the annualized rate of EDSS change. CONCLUSION: Among registrants of MSBase, male relapse-onset patients accumulate disability faster than female patients. In contrast, the rate of disability accumulation between male and female patients with primary progressive MS is similar.
Konular
Atıflar
OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.
189 atıf
OpenAlex cited_by_count (önbellek / veritabanı)
Yerel katalogda bu makaleye atıf yapan 19 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).
- Defining secondary progressive multiple sclerosis 2016
- Early clinical markers of aggressive multiple sclerosis 2020
- First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis 2025
- First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis 2025
- Early clinical markers of aggressive multiple sclerosis 2019
- Determinants of disability development in patients with multiple sclerosis 2021
- Determinants of therapeutic lag in multiple sclerosis 2021
- Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS 2022
- Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS 2022
- Comparative Efficacy and Safety of Extended Versus Standard Interval Dosing of Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients: A Multicenter Analysis 2025